Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01877187 · ClinicalTrials.gov registry record · Phase 2
Lipiodol as an Imaging Biomarker in Patients With Primary and Metastatic Liver Cancer
A Phase 2 study, sponsored by Yale University.
- Completed
- Registry status
- Phase 2
- Development phase
- 39
- Enrollment target
NCT01877187 is a Phase 2 study that has completed, run by Yale University. The registered enrollment target is 39 participants.
The verdict
NCT01877187, a Phase 2 study, has completed, sponsored by Yale University.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 39 participants
- Enrollment target
Study Summary
The purpose of this study is to determine the whether Lipiodol can be used as an imaging biomarker, predicting tumor response to therapy in patients with primary and metastatic liver cancer. Lipiodol-based transarterial chemoembolization (TACE) has been an accepted standard of care procedure for unresectable liver lesions for several decades. Lipiodol is used as a carrier for chemotherapy agents and also as an occlusion agent. In TACE procedures, Lipiodol is mixed with the chemotherapy agent(s) and delivered to the tumor via the hepatic artery, causing necrosis of the targeted tumor(s). Response to therapy will be evaluated every 1, 3 and 6 months by clinic visits, MRI/CT/PET scans and blood tests (to include assessment of liver function and tumor markers).
Interventions
- DRUG Lipiodol
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 39 participants |
| Start Date | 2013-04 |
| Est. Completion | 2020-02 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01877187
The ClinicalTrials.gov registry entry for NCT01877187 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 39 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Yale University, which has 1,492 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Lipiodol is the first listed.
NCT01877187 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01877187 about?
NCT01877187 is a clinical study titled "Lipiodol as an Imaging Biomarker in Patients With Primary and Metastatic Liver Cancer". The purpose of this study is to determine the whether Lipiodol can be used as an imaging biomarker, predicting tumor response to therapy in patients with primary and metastatic liver cancer. Lipiodol-based transarterial chemoembolization (TACE) has been an accepted standard of care procedure for unr...
What is the current status of trial NCT01877187?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 39 participants. The study started on 2013-04. Estimated completion is 2020-02.
What interventions are being tested in trial NCT01877187?
The interventions under investigation include: Lipiodol (DRUG).
Who is sponsoring clinical trial NCT01877187?
This trial is sponsored by Yale University, which has 1,492 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.